Cytokinetics, IncorporatedCYTKNASDAQ
Loading
EPS Growth AcceleratingAccelerating
Percentile Rank90
3Y CAGR+16.8%
Year-over-Year Change
Year-over-year earnings per share growth rate
3Y CAGR
+16.8%/yr
vs +31.5%/yr prior
Acceleration
-14.6pp
Decelerating
Percentile
P90
Near historical high
vs 3Y Ago
1.6x
Solid growth
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 41.57% |
| Q3 2025 | -127.68% |
| Q2 2025 | 17.65% |
| Q1 2025 | -7.09% |
| Q4 2024 | 6.62% |
| Q3 2024 | -3.82% |
| Q2 2024 | 1.50% |
| Q1 2024 | 3.62% |
| Q4 2023 | -2.22% |
| Q3 2023 | -0.75% |
| Q2 2023 | 1.47% |
| Q1 2023 | 2.16% |
| Q4 2022 | 26.06% |
| Q3 2022 | -452.94% |
| Q2 2022 | 71.43% |
| Q1 2022 | -230.56% |
| Q4 2021 | 62.11% |
| Q3 2021 | -10.47% |
| Q2 2021 | -30.30% |
| Q1 2021 | -6.45% |
| Q4 2020 | -1233.33% |
| Q3 2020 | 93.16% |
| Q2 2020 | -3.03% |
| Q1 2020 | -26.92% |
| Q4 2019 | -4.00% |
| Q3 2019 | 10.71% |
| Q2 2019 | -3.70% |
| Q1 2019 | -12.50% |
| Q4 2018 | -20.00% |
| Q3 2018 | 21.57% |
| Q2 2018 | 8.93% |
| Q1 2018 | 25.33% |
| Q4 2017 | -25.00% |
| Q3 2017 | 0.00% |
| Q2 2017 | 3.23% |
| Q1 2017 | -444.44% |
| Q4 2016 | -77.50% |
| Q3 2016 | 375.86% |
| Q2 2016 | 6.45% |
| Q1 2016 | -29.17% |